Advertisement

Translational Stroke Research

, Volume 10, Issue 5, pp 546–556 | Cite as

From Analysis of Ischemic Mouse Brain Proteome to Identification of Human Serum Clusterin as a Potential Biomarker for Severity of Acute Ischemic Stroke

  • Hailong Song
  • Hui Zhou
  • Zhe Qu
  • Jie Hou
  • Weilong Chen
  • Weiwu Cai
  • Qiong Cheng
  • Dennis Y. Chuang
  • Shanyan Chen
  • Shuwei Li
  • Jilong Li
  • Jianlin Cheng
  • C. Michael Greenlief
  • Yuan Lu
  • Agnes Simonyi
  • Grace Y. Sun
  • Chenghan Wu
  • Jiankun Cui
  • Zezong GuEmail author
Original Article

Abstract

Ischemic stroke is a devastating neurological disease that can cause permanent brain damage, but to date, few biomarkers are available to reliably assess the severity of injury during acute onset. In this study, quantitative proteomic analysis of ischemic mouse brain detected the increase in expression levels of clusterin (CLU) and cystatin C (CST3). Since CLU is a secretary protein, serum samples (n = 70) were obtained from acute ischemic stroke (AIS) patients within 24 h of stroke onset and together with 70 matched health controls. Analysis of CLU levels indicated significantly higher levels in AIS patients than healthy controls (14.91 ± 4.03 vs. 12.79 ± 2.22 ng/L; P = 0.0004). Analysis of serum CST3 also showed significant increase in AIS patients as compared with healthy controls (0.90 ± 0.19 vs. 0.84 ± 0.12 ng/L; P = 0.0064). The serum values of CLU were also positively correlated with the NIH Stroke Scale (NIHSS) scores, the time interval after stroke onset, as well as major stroke risk factors associated with lipid profile. These data demonstrate that elevated levels of serum CLU and CST3 are independently associated with AIS and may serve as peripheral biomarkers to aid clinical assessment of AIS and its severity. This pilot study thus contributes to progress toward preclinical proteomic screening by using animal models and allows translation of results from bench to bedside.

Keywords

Biomarkers Ischemic stroke Clusterin Cystatin C Proteomics 

Notes

Acknowledgements

We thank Dr. Jin-Moo Lee of Washington University in St. Louis for scientific comments and Mr. Garrett Ungerer for editing of the manuscript.

Funding Sources

This work is partially supported by a research fund from the Department of Pathology and Anatomical Sciences at the University of Missouri-Columbia (MU) (ZG) and by a grant from the National Institutes of Health National Center for Complementary and Integrative Health (P50AT006273) to the MU Center for Botanical Interaction Studies. The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Statement of Human Rights/Statement on the Welfare of Animals

Ethical approval for human rights: “All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.”

Ethical Approval for the Welfare of Animals

“All procedures performed in studies involving animals were in accordance with the ethical standards of the University of Missouri approved protocols for the Care and Use of Laboratory Animals at which the studies were conducted.”

Informed consent

“Informed consent was obtained from all individual participants included in the study.”

Supplementary material

12975_2018_675_MOESM1_ESM.pdf (1.3 mb)
ESM 1 (PDF 1286 kb)
12975_2018_675_MOESM2_ESM.xlsx (4.5 mb)
Supplementary Table 1 (XLSX 4633 kb)
12975_2018_675_MOESM3_ESM.xlsx (4.4 mb)
Supplementary Table 2 (XLSX 4512 kb)
12975_2018_675_MOESM4_ESM.xlsx (4.2 mb)
Supplementary Table 3 (XLSX 4319 kb)

References

  1. 1.
    van der Worp HB, van Gijn J. Clinical practice. Acute ischemic stroke. N Engl J Med. 2007;357(6):572–9.  https://doi.org/10.1056/NEJMcp072057.CrossRefGoogle Scholar
  2. 2.
    Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(7):2064–89.  https://doi.org/10.1161/STR.0b013e318296aeca.CrossRefGoogle Scholar
  3. 3.
    Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.  https://doi.org/10.1161/CIR.0000000000000152.Google Scholar
  4. 4.
    Catanese L, Tarsia J, Fisher M. Acute ischemic stroke therapy overview. Circ Res. 2017;120(3):541–58.  https://doi.org/10.1161/CIRCRESAHA.116.309278.CrossRefGoogle Scholar
  5. 5.
    Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke. 2009;40(5):e380–9.  https://doi.org/10.1161/STROKEAHA.108.528752.CrossRefGoogle Scholar
  6. 6.
    Jickling GC, Sharp FR. Biomarker panels in ischemic stroke. Stroke. 2015;46(3):915–20.  https://doi.org/10.1161/STROKEAHA.114.005604.CrossRefGoogle Scholar
  7. 7.
    Maas MB, Furie KL. Molecular biomarkers in stroke diagnosis and prognosis. Biomark Med. 2009;3(4):363–83.  https://doi.org/10.2217/bmm.09.30.CrossRefGoogle Scholar
  8. 8.
    Carpenter KL, Czosnyka M, Jalloh I, Newcombe VF, Helmy A, Shannon RJ, et al. Systemic, local, and imaging biomarkers of brain injury: more needed, and better use of those already established? Front Neurol. 2015;6:26.  https://doi.org/10.3389/fneur.2015.00026.CrossRefGoogle Scholar
  9. 9.
    Lindsey ML, Mayr M, Gomes AV, Delles C, Arrell DK, Murphy AM, et al. Transformative impact of proteomics on cardiovascular health and disease: a scientific statement from the American Heart Association. Circulation. 2015;132(9):852–72.  https://doi.org/10.1161/CIR.0000000000000226.CrossRefGoogle Scholar
  10. 10.
    Ning M, Lo EH. Opportunities and challenges in omics. Transl Stroke Res. 2010;1(4):233–7.  https://doi.org/10.1007/s12975-010-0048-y.CrossRefGoogle Scholar
  11. 11.
    Ning M, Lopez M, Cao J, Buonanno FS, Lo EH. Application of proteomics to cerebrovascular disease. Electrophoresis. 2012;33(24):3582–97.  https://doi.org/10.1002/elps.201200481.CrossRefGoogle Scholar
  12. 12.
    Swan AL, Mobasheri A, Allaway D, Liddell S, Bacardit J. Application of machine learning to proteomics data: classification and biomarker identification in postgenomics biology. OMICS. 2013;17(12):595–610.CrossRefGoogle Scholar
  13. 13.
    Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, Allard L, Hochstrasser DF, Sanchez JC. Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol Cell Proteomics. 2004;3(1):66–72.  https://doi.org/10.1074/mcp.M300066-MCP200.CrossRefGoogle Scholar
  14. 14.
    Ning M, Sarracino DA, Kho AT, Guo S, Lee SR, Krastins B, et al. Proteomic temporal profile of human brain endothelium after oxidative stress. Stroke. 2011;42(1):37–43.  https://doi.org/10.1161/STROKEAHA.110.585703.CrossRefGoogle Scholar
  15. 15.
    Garcia-Berrocoso T, Penalba A, Boada C, Giralt D, Cuadrado E, Colome N, et al. From brain to blood: new biomarkers for ischemic stroke prognosis. J Proteome. 2013;94:138–48.  https://doi.org/10.1016/j.jprot.2013.09.005.CrossRefGoogle Scholar
  16. 16.
    Ramsubramaniam N, Tao F, Li S, Marten MR. Cost-effective isobaric tagging for quantitative phosphoproteomics using DiART reagents. Mol BioSyst. 2013;9(12):2981–7.  https://doi.org/10.1039/c3mb70358d.CrossRefGoogle Scholar
  17. 17.
    Ramsubramaniam N, Tao F, Li S, Marten MR. Novel and cost-effective 6-plex isobaric tagging reagent, DiART, is effective for identification and relative quantification of complex protein mixtures using PQD fragmentation. J Mass Spectrom. 2013;48(9):1032–41.  https://doi.org/10.1002/jms.3249.CrossRefGoogle Scholar
  18. 18.
    Weinstein G, Beiser AS, Preis SR, Courchesne P, Chouraki V, Levy D, et al. Plasma clusterin levels and risk of dementia, Alzheimer’s disease, and stroke. Alzheimers Dement (Amst). 2016;3:103–9.  https://doi.org/10.1016/j.dadm.2016.06.005.Google Scholar
  19. 19.
    Cevik O, Baykal AT, Sener A. Platelets proteomic profiles of acute ischemic stroke patients. PLoS One. 2016;11(6):e0158287.  https://doi.org/10.1371/journal.pone.0158287.CrossRefGoogle Scholar
  20. 20.
    Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, et al. A potential endophenotype for Alzheimer’s disease: cerebrospinal fluid clusterin. Neurobiol Aging. 2016;37:208 e1–9.  https://doi.org/10.1016/j.neurobiolaging.2015.09.009.CrossRefGoogle Scholar
  21. 21.
    Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36(1):29–34.  https://doi.org/10.1053/ajkd.2000.8237.CrossRefGoogle Scholar
  22. 22.
    Ni L, Lu J, Hou LB, Yan JT, Fan Q, Hui R, et al. Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke. 2007;38(12):3287–8.  https://doi.org/10.1161/STROKEAHA.107.489625.CrossRefGoogle Scholar
  23. 23.
    Fang Z, Deng J, Wu Z, Dong B, Wang S, Chen X, et al. Cystatin C is a crucial endogenous protective determinant against stroke. Stroke. 2017;48(2):436–44.  https://doi.org/10.1161/STROKEAHA.116.014975.CrossRefGoogle Scholar
  24. 24.
    Chuang DY, Cui J, Simonyi A, Engel VA, Chen S, Fritsche KL et al. Dietary Sutherlandia and elderberry mitigate cerebral ischemia-induced neuronal damage and attenuate p47phox and phospho-ERK1/2 expression in microglial cells. ASN Neuro. 2014;6(6).  https://doi.org/10.1177/1759091414554946.
  25. 25.
    Johnson MC, Song H, Cui J, Mossine VV, Gu Z, Greenlief CM. Development of a method and validation for the quantitation of FruArg in mice plasma and brain tissue using UPLC–MS/MS. ACS Omega. 2016;1(4):663–8.  https://doi.org/10.1021/acsomega.6b00220.CrossRefGoogle Scholar
  26. 26.
    Qu Z, Meng F, Bomgarden RD, Viner RI, Li J, Rogers JC, et al. Proteomic quantification and site-mapping of S-nitrosylated proteins using isobaric iodoTMT reagents. J Proteome Res. 2014;13(7):3200–11.  https://doi.org/10.1021/pr401179v.CrossRefGoogle Scholar
  27. 27.
    Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47(2):581–641.CrossRefGoogle Scholar
  28. 28.
    Lyden PD, Lu M, Levine SR, Brott TG, Broderick J, Group NrSS. A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity. Stroke. 2001;32(6):1310–7.CrossRefGoogle Scholar
  29. 29.
    Miyake H, Muramaki M, Furukawa J, Kurahashi T, Fujisawa M. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. Urology. 2010;75(2):454–9.  https://doi.org/10.1016/j.urology.2009.08.029.CrossRefGoogle Scholar
  30. 30.
    Shimizu-Tokiwa A, Kobata M, Io H, Kobayashi N, Shou I, Funabiki K, et al. Serum cystatin C is a more sensitive marker of glomerular function than serum creatinine. Nephron. 2002;92(1):224–6.CrossRefGoogle Scholar
  31. 31.
    Wang J, Jin H, Hua Y, Keep RF, Xi G. Role of protease-activated receptor-1 in brain injury after experimental global cerebral ischemia. Stroke. 2012;43(9):2476–82.  https://doi.org/10.1161/STROKEAHA.112.661819.CrossRefGoogle Scholar
  32. 32.
    Kristian T, Hu B. Guidelines for using mouse global cerebral ischemia models. Transl Stroke Res. 2013;4(3):343–50.  https://doi.org/10.1007/s12975-012-0236-z.CrossRefGoogle Scholar
  33. 33.
    Chen Z, Wang Q, Lin L, Tang Q, Edwards JL, Li S, et al. Comparative evaluation of two isobaric labeling tags, DiART and iTRAQ. Anal Chem. 2012;84(6):2908–15.  https://doi.org/10.1021/ac203467q.CrossRefGoogle Scholar
  34. 34.
    Song H, Lu Y, Qu Z, Mossine VV, Martin MB, Hou J, et al. Effects of aged garlic extract and FruArg on gene expression and signaling pathways in lipopolysaccharide-activated microglial cells. Sci Rep. 2016;6:35323.  https://doi.org/10.1038/srep35323.CrossRefGoogle Scholar
  35. 35.
    Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007;2(10):2366–82.  https://doi.org/10.1038/nprot.2007.324.CrossRefGoogle Scholar
  36. 36.
    Arrell DK, Terzic A. Network systems biology for drug discovery. Clin Pharmacol Ther. 2010;88(1):120–5.  https://doi.org/10.1038/clpt.2010.91.CrossRefGoogle Scholar
  37. 37.
    Jauch EC WK, Carrozzella J. Proteomic analyses demonstrates ultra-early elevations of inflammation-sensitive plasma proteins following ischemic stroke. 5th World Stroke Congress, Vancouver BC, Canada. 2004.Google Scholar
  38. 38.
    Jensen MB, Chacon MR, Sattin JA, Aleu A, Lyden PD. The promise and potential pitfalls of serum biomarkers for ischemic stroke and transient ischemic attack. Neurologist. 2008;14(4):243–6.  https://doi.org/10.1097/NRL.0b013e31815a9945.CrossRefGoogle Scholar
  39. 39.
    Chow SL, Maisel AS, Anand I, Bozkurt B, De Boer RA, Felker GM, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. 2017;135(22):e1054–e91.CrossRefGoogle Scholar
  40. 40.
    Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res. 2010;16(4):1088–93.  https://doi.org/10.1158/1078-0432.CCR-09-2917.CrossRefGoogle Scholar
  41. 41.
    Imhof A, Charnay Y, Vallet PG, Aronow B, Kovari E, French LE, et al. Sustained astrocytic clusterin expression improves remodeling after brain ischemia. Neurobiol Dis. 2006;22(2):274–83.  https://doi.org/10.1016/j.nbd.2005.11.009.CrossRefGoogle Scholar
  42. 42.
    Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H, et al. The role of clusterin in amyloid-beta-associated neurodegeneration. JAMA Neurol. 2014;71(2):180–7.  https://doi.org/10.1001/jamaneurol.2013.4560.CrossRefGoogle Scholar
  43. 43.
    Santilli G, Aronow BJ, Sala A. Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J Biol Chem. 2003;278(40):38214–9.  https://doi.org/10.1074/jbc.C300252200.CrossRefGoogle Scholar
  44. 44.
    Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol. 2005;7(9):909–15.  https://doi.org/10.1038/ncb1291.CrossRefGoogle Scholar
  45. 45.
    Wehrli P, Charnay Y, Vallet P, Zhu G, Harmony J, Aronow B, et al. Inhibition of post-ischemic brain injury by clusterin overexpression. Nat Med. 2001;7(9):977–9.  https://doi.org/10.1038/nm0901-977.CrossRefGoogle Scholar
  46. 46.
    Han BH, DeMattos RB, Dugan LL, Kim-Han JS, Brendza RP, Fryer JD, et al. Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. Nat Med. 2001;7(3):338–43.  https://doi.org/10.1038/85487.CrossRefGoogle Scholar
  47. 47.
    Kroksveen AC, Aasebo E, Vethe H, Van Pesch V, Franciotta D, Teunissen CE, et al. Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. J Proteome. 2013;78:312–25.  https://doi.org/10.1016/j.jprot.2012.09.037.CrossRefGoogle Scholar
  48. 48.
    Tu C, Beharry KD, Shen X, Li J, Wang L, Aranda JV, et al. Proteomic profiling of the retinas in a neonatal rat model of oxygen-induced retinopathy with a reproducible ion-current-based MS1 approach. J Proteome Res. 2015;14(5):2109–20.  https://doi.org/10.1021/pr501238m.CrossRefGoogle Scholar
  49. 49.
    Turk V, Turk B, Guncar G, Turk D, Kos J. Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv Enzym Regul. 2002;42:285–303.CrossRefGoogle Scholar
  50. 50.
    Yan S, Sloane BF. Molecular regulation of human cathepsin B: implication in pathologies. Biol Chem. 2003;384(6):845–54.  https://doi.org/10.1515/BC.2003.095.CrossRefGoogle Scholar
  51. 51.
    Hakansson K, Huh C, Grubb A, Karlsson S, Abrahamson M. Mouse and rat cystatin C: Escherichia coli production, characterization and tissue distribution. Comp Biochem Physiol B Biochem Mol Biol. 1996;114(3):303–11.CrossRefGoogle Scholar
  52. 52.
    Hoke M, Amighi J, Mlekusch W, Schlager O, Exner M, Sabeti S, et al. Cystatin C and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke. 2010;41(4):674–9.  https://doi.org/10.1161/STROKEAHA.109.573162.CrossRefGoogle Scholar
  53. 53.
    Huang GX, Ji XM, Ding YC, Huang HY. Association between serum cystatin C levels and the severity or potential risk factors of acute ischemic stroke. Neurol Res. 2016;38(6):518–23.  https://doi.org/10.1080/01616412.2016.1187825.CrossRefGoogle Scholar
  54. 54.
    Yin GN, Lee HW, Cho JY, Suk K. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res. 2009;1265:158–70.  https://doi.org/10.1016/j.brainres.2009.01.058.CrossRefGoogle Scholar
  55. 55.
    Martins-de-Souza D, Guest PC, Harris LW, Vanattou-Saifoudine N, Webster MJ, Rahmoune H, et al. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl Psychiatry. 2012;2:e87.  https://doi.org/10.1038/tp.2012.13.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018
corrected publication December/2018

Authors and Affiliations

  • Hailong Song
    • 1
    • 2
  • Hui Zhou
    • 1
    • 2
  • Zhe Qu
    • 1
    • 2
  • Jie Hou
    • 2
    • 3
  • Weilong Chen
    • 4
  • Weiwu Cai
    • 4
  • Qiong Cheng
    • 5
  • Dennis Y. Chuang
    • 1
    • 2
    • 6
  • Shanyan Chen
    • 1
    • 2
  • Shuwei Li
    • 7
  • Jilong Li
    • 2
    • 3
  • Jianlin Cheng
    • 2
    • 3
  • C. Michael Greenlief
    • 8
  • Yuan Lu
    • 9
  • Agnes Simonyi
    • 2
    • 6
  • Grace Y. Sun
    • 1
    • 2
    • 6
  • Chenghan Wu
    • 4
  • Jiankun Cui
    • 1
    • 2
  • Zezong Gu
    • 1
    • 2
    Email author
  1. 1.Department of Pathology & Anatomical SciencesUniversity of MissouriColumbiaUSA
  2. 2.Center for Botanical Interaction StudiesUniversity of MissouriColumbiaUSA
  3. 3.Computer ScienceUniversity of MissouriColumbiaUSA
  4. 4.Department of Neurologythe Second Affiliated Clinical College of Fujian University of Traditional Chinese MedicineFuzhouChina
  5. 5.Department of NeurologyFujian Provincial HospitalFuzhouChina
  6. 6.BiochemistryUniversity of MissouriColumbiaUSA
  7. 7.Department of Chemistry and BiochemistryUniversity of MarylandCollege ParkUSA
  8. 8.ChemistryUniversity of MissouriColumbiaUSA
  9. 9.Xiphophorus Genetic Stock CenterTexas State UniversitySan MarcosUSA

Personalised recommendations